Association of Alanine-Valine Manganese Superoxide Dismutase Gene Polymorphism and Microheterogeneity Manganese Superoxide Dismutase Activity in Breast Cancer and Benign Breast Tissue

Abstract

PurposeAlthough the etiology of breast cancer is multifactorial, oxidative stress plays an important role in carcinogenesis. In this study, manganese superoxide dismutase (MnSOD) gene polymorphism and activity were evaluated in benign and breast cancer tissue.MethodsOne hundred and one females were enrolled in this study, 65 who were histopathologically diagnosed with breast cancer and 46 who were benign patients. MnSOD enzyme activity was determined using an indirect competitive inhibition assay and MnSOD gene polymorphism using poly merase chain reaction and agarose gel electrophoresis.ResultsMnSOD enzymatic activity (79.83±42.14) was lower in breast cancer tissue compared to benign tumors (236.18±46.37). At the same time, MnSOD enzymatic activity among Ala/Val patients was significantly lower in breast cancer tissue (39.19±7.33) than in Val/Val malignant breast tumors tissue (96.9±22.9). MnSOD enzymatic activity was significantly lower in Val/Val cancer tissue (96.9±22.9) than in benign tissue (255.44±42.7).ConclusionBreast cancer tumors contain less MnSOD than benign breast samples. Patients with Ala/Val polymorphism had reduced MnSOD activity compared to patients with Val/Val breast cancer. Ala/Val gene polymorphism may be a risk factor associated with more advanced breast cancer stage. MnSOD gene polymorphism Ala/Val may be a risk factor associated with more advanced breast cancer stage, and reduction of MnSOD activity may be a mechanism of the progression of benign to malignant tumors. Further investigations are needed to evaluate the role of MnSOD in breast cancer progression.

Manganese Superoxide Dismutase (MnSOD Val-9Ala) Gene Polymorphism and Susceptibility to Gastric Cancer

“…Similar to our study, Atoum et al (2012) observed that the Val/Val allele of MnSOD Val-9Ala was correlated to a significantly decreased risk for breast cancer disease in Jordanian population. Also, Augusto et al (2007b) indicated that gastritis was characteristic by an oxidative stress with significant absence of MnSOD and GPX expression.…”

Association betweenMnSODVal16Ala Polymorphism and Cancer Risk: Evidence from 33,098 Cases and 37,831 Controls

“…Overall, 88 studies with 33,098 cases and 37,831 controls were included in this meta-analysis. Of the 88 studies, 24 studies focused on breast cancer [ 9 – 11 , 16 , 38 , 60 , 61 , 68 , 69 , 71 , 72 , 77 , 88 , 93 , 96 , 97 , 100 , 105 , 109 , 114 , 119 , 122 , 127 ]; 17 on prostate cancer [ 37 , 66 , 74 , 79 , 82 , 85 , 86 , 89 , 95 , 106 , 111 , 113 , 120 , 125 , 128 ]; six for each of the following cancer types, such as lung cancer [ 7 , 17 , 18 , 65 , 92 , 118 ], bladder cancer [ 8 , 15 , 67 , 75 , 112 , 117 ], and pancreatic cancer [ 64 , 91 , 102 , 107 , 108 , 121 ]; five on colorectal cancer [ 13 , 63 , 73 , 94 , 101 ]; three for each of the following cancer types, such as ovarian cancer [ 70 , 81 , 87 ], hepatocellular carcinoma [ 98 , 99 , ...…”

“…b Cengiz et al [ 15 ], Cheng et al [ 106 ], and Zhang et al [ 108 ] were only calculated for the recessive model. c Ho et al [ 18 ], Ergen et al [ 79 ], and Atoum et al [ 109 ] were only calculated for the heterozygous model, dominant model, and allele comparison, and the number of Ala/Ala genotype was zero. d Mixed: which included more than one genotyping methods.…”

Application of metabolomics in the diagnosis of breast cancer: a systematic review

“…Based on clinical metabolomic studies, tyrosine and alanine shared the highest frequency with 12 hits, indicating they might be sensitive metabolites in the diagnosis of BC. Although the changing trend of tyrosine among different studies were inconsistent, previous research has demonstrated that tyrosine deficiency could result in BC cell growth arrest [69], and inhibition of tumor growth has been confirmed in low phenylalanine and tyrosine diets in an animal study [70]. Recent studies also showed that alanine had a significant difference between estrogen receptor positive and estrogen receptor negative breast cancer [71][72].…”